Avacta

Avacta will announce its unaudited preliminary results for the year ended December 31, 2025 on May 19, 2026. avacta.com/notice-of-prel… #AVCT

For those who were unable to attend in person, the event was professionally recorded and the video will be made available on the Avacta website in due course. #AVCT

Thank you to everyone who attended today's Science Day. The whole team really enjoyed being able to present the exciting progress being made and speak to many of you in person. We are so grateful for your continued support! #AVCT

Avacta will today present two new developments at its Science Day 2026 event. Comparative analyses of AVA6103 compared with now two approved Antibody-Drug Conjugates (ADCs). Also, updated in vivo studies of the dual payload delivery program, AVA6207. avacta.com/avacta-present… #AVCT

Salivary gland cancer, a rare subset of head and neck cancers, remains an area of significant unmet need. Through our pre|CISION® platform, we are committed to advancing new options for these patients. To everyone whose advocacy makes this research possible, thank you. #AVCT

As Head and Neck Cancer Awareness Month draws to a close, we recognize the patients, families, and advocates whose courage and persistence drive progress in these complex diseases. #AVCT #HeadAndNeckCancerAwareness #SalivaryGlandCancer #HopeWithoutCompromise #Oncology #preCISION

For those unable to join in person, a recording will be made available on our website once edited. #AVCT

We're looking forward to welcoming attendees on May 6 to the Royal Society of Chemistry, London, for presentations on our scientific achievements and the road ahead for our tumor-activated oncology platform, followed by a reception. #AVCT

In this video presentation, the Avacta team discusses the second presentation from this week’s #AACR26 Annual Meeting, our dual payload technology. avacta.wistia.com/medias/xktyxrb… #AVCT

Thank you to everyone who stopped by our posters and connected with our team. We’re heading home energized and more focused than ever on the road ahead. Read more: avacta.com/avacta-data-at… #AVCT

That’s a wrap on #AACR2026! We were proud to present two posters showcasing preclinical and translational data from our pre|CISION platform. It was a great week of conversations with researchers, clinicians, and industry colleagues. #AVCT

In this video presentation, the Avacta team discuss the AVA6103 (FAP-EXd) preclinical and clinical trial in progress highlights presented at this week’s #AACR26 Annual Meeting. avacta.wistia.com/medias/xrtdvmv… (A second presentation will be coming soon!) #AVCT

Avacta is giving two presentations today at the American Association for Cancer Research (AACR) Annual Meeting 2026.  avacta.com/avacta-data-at… #AVCT

In this episode of the Rx for Biotech podcast, Avacta CEO Christina Coughlin shares her journey from early work in CAR-T cell therapy and immuno-oncology to leading Avacta’s innovative pre|CISION peptide drug conjugate platform. youtube.com/watch?v=00Uvub… #AVCT #Biotech #Oncology

We’re proud to congratulate our CEO, @coughlin582 on her selection as one of Citeline In Vivo’s 2026 Rising Leaders. avacta.com/avacta-ceo-chr… #AVCT

Avacta today provides a business update through the first quarter of 2026. avacta.com/q1-2026-busine… #AVCT

If you were not able to secure a seat to attend, rest assured the sessions are being professionally recorded and the edited video will be available as soon as possible after the event on the website, no more than a week later. As always, we are grateful for the support. #AVCT

Our #AVCT team are humbled at the incredible response to our 2026 Science Day invitation earlier today.  As the venue is now at full capacity, the registration has closed.

We are pleased to invite colleagues and investors to our 2026 Science Day: The Next Chapter of pre|CISION. Join us in Central London on May 6 at the Royal Society of Chemistry for presentations followed by a reception. avacta.com/avacta-announc… #AVCT

Great discussion at the World Clinical Biomarkers & Companion Diagnostics Summit in London, where Ruairidh Edwards presented on Avacta’s biomarker-driven approach to guide indication selection for pre|CISION platform conjugates. Strong audience engagement and follow-up! #AVCT